Parametric Portfolio Associates’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Parametric Portfolio Associates’s Portfolio NGM Stock Details NGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$269K	Sell	17,629 -857	-5%	-$13.4K	﹤0.01%	3327
2021 Q4	$327K	Sell	18,486 -13,255	-42%	-$254K	﹤0.01%	3249
2021 Q3	$667K	Buy	31,741 +2,429	+8%	+$53.5K	﹤0.01%	2973
2021 Q2	$578K	Sell	29,312 -18,330	-38%	-$429K	﹤0.01%	3020
2021 Q1	$1.39M	Buy	47,642 +12,156	+34%	+$340K	﹤0.01%	2993
2020 Q4	$1.07M	Sell	35,486 -1,545	-4%	-$33.8K	﹤0.01%	3016
2020 Q3	$589K	Sell	37,031 -317	-0.8%	-$5.78K	﹤0.01%	3193
2020 Q2	$737K	Sell	37,348 -805	-2%	-$15.4K	﹤0.01%	3083
2020 Q1	$470K	Buy	38,153 +22,213	+139%	+$363K	﹤0.01%	3191
2019 Q4	$295K	Sell	15,940 -3,388	-18%	-$49.5K	﹤0.01%	3574
2019 Q3	$268K	Buy	+19,328	New	+$290K	﹤0.01%	3596

Other funds holding NGM

Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return

RCP

Rho Capital Partners New York $20.4M AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

PIM

Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return

Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Parametric Portfolio Associates's NGM Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its NGM Biopharmaceuticals, Inc. Common Stock (NGM) stake by 4.6% in Q1 2022, selling an estimated $13.4K and leaving 17,629 shares worth $269K. The position accounts for ﹤0.01% of the portfolio, ranked #3327.

Parametric Portfolio Associates first reported a position in NGM in Q3 2019 and has held it in 11 quarters since. The position peaked at $1.39M in Q1 2021. 114 funds tracked by Wall St. Rank hold NGM as of Q1 2022.

Parametric Portfolio Associates held 17,629 shares of NGM Biopharmaceuticals, Inc. Common Stock worth $269K as of Q1 2022.
Parametric Portfolio Associates sold 857 NGM Biopharmaceuticals, Inc. Common Stock shares in Q1 2022, an estimated $13.4K.
NGM Biopharmaceuticals, Inc. Common Stock made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3327 holding.
Parametric Portfolio Associates first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q3 2019 and has held it in 11 quarters since.
Parametric Portfolio Associates's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $1.39M in Q1 2021.
114 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.